Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment

ConditionCancer

Trial statusNot yet recruiting

Trial phasePhase 2, Phase 3

Trial typeInterventional

Biological sexFemale

Age30-50

SponsorThe University of Texas Medical Branch, Galveston

About this trial

This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.

Eligibility criteria

Qualifiers

Female

Ages 30 - 50 years

Self-reported menses occurrence within past 12 months

Diagnosis of ER+/HER2- breast cancer

Disqualifiers

Untreated thyroid disorder

Untreated diabetes

BMI >30

Current treatment with metformin

Trial design

Treatments tested in this trial

Sildenafil

Treatment groups

30 Participants

are divided into 2 treatment groups

Sponsors and collaborators

The University of Texas Medical Branch, Galveston

Lead sponsor

Source ClinicalTrials.gov